Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Synthesis of natural molecule could lead to better anti-cancer drugs

In early 2007, Northwestern University chemist Karl Scheidt's interest was piqued when marine chemist Amy Wright reported in the Journal of Natural Products that a new natural compound derived from an uncommon deep-sea sponge was extremely effective at inhibiting cancer cell growth.

24 Jan 2008

New method enables design, production of extremely novel drugs

A new chemical synthesis method based on a catalyst worth many times the price of gold and providing a far more efficient and economical method than traditional ones for designing and manufacturing extremely novel pharmaceutical compounds is described by its University at Buffalo developers in a review article in the current issue of Nature.

24 Jan 2008

Unique fungal collection could hold key to future antibiotics

Scientists at Royal Holloway, University of London have joined forces with CABI to establish a facility to screen for potential new antibiotics.

23 Jan 2008

Cancer Research UK invests 10 million pounds in drug discovery

Project leaders at Imperial College London, University of Oxford, University of Strathclyde and The School of Pharmacy in London will each receive 500k pounds per year for five years to develop anti-cancer drugs.

17 Jan 2008

NicOx extends ophthalmology agreement with Pfizer

NicOx S.A. has announced it has signed an extension of its March 2006 collaboration agreement, which grants Pfizer Inc the exclusive right to apply its proprietary nitric oxide-donating technology to drug discovery research in the field of ophthalmology.

9 Jan 2008

Two genes are important key to regulating immune response

A research team at Weill Cornell Medical College in New York City has identified two genes that may be crucial to the production of an immune system cytokine called interleukin-10 (IL-10)

2 Jan 2008

New drug targets may fight tuberculosis and other bacterial infections in novel way

Over the course of the 20th Century, doctors waged war against infectious bacterial illness with the best new weapon they had: antibiotics.

28 Dec 2007

Paradigm shift in TB: virulence factors, not antibiotics

Over the course of the 20th Century, doctors waged war against infectious bacterial illness with the best new weapon they had: antibiotics.

27 Dec 2007

FDA Critical Path Initiative addresses differences between women's and men's health outcomes

Advanced medical technology and analysis methods now being promoted through the Food and Drug Administration's Critical Path Initiative to facilitate the development of drugs, biologics and devices can help address differences between women and men in the detection and treatment of disease, according to a paper published in the Winter 2007 issue of Drug Discovery Today: Technologies.

20 Dec 2007

New biochip technology could eliminate animal testing in chemicals and cosmetics industries

A new biochip technology could eliminate animal testing in the chemicals and cosmetics industries, and drastically curtail its use in the development of new pharmaceuticals, according to new findings from a team of researchers at Rensselaer Polytechnic Institute, the University of California at Berkeley, and Solidus Biosciences Inc.

18 Dec 2007

Cheaper drugs now closer to realization with new DropArray technology

A standard laboratory tool for measuring pharmacological activity of biological substances and performing other related tests may soon be replaced by a new miniaturized bioassay that will be faster, cheaper and more efficient for scientists to use, with new technology developed by Singapore's Institute of Bioengineering and Nanotechnology (IBN).

17 Dec 2007

Odyssey Thera granted U.S. patent for animal imaging

Odyssey Thera, Inc. has announced that the United States Patent and Trademark Office granted U.S. Patent No. 7,306,914, entitled "Protein-fragment Complementation Assays (PCA) in whole animals: applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy.

13 Dec 2007

SuperGen's CLIMB technology identifies lead Pim kinase inhibitors

SuperGen Inc. has announced the presentation of data that describe how its proprietary CLIMB technology was used in lead development and design of small molecule Pim kinase inhibitors (Poster 845, Abstract 2655).

10 Dec 2007

Scientists strike blow in super bugs struggle

Scientists from the University of Manchester have pioneered new ways of tweaking the molecular structure of antibiotics - an innovation that could be crucial in the fight against powerful super bugs.

From The University of Manchester 5 Dec 2007

Immtech and BioAlliance sign agreement on Pafuramidine for African sleeping sickness

Immtech Pharmaceuticals has announced that the Company has granted an exclusive license to BioAlliance Pharma SA to commercialize Immtech's oral drug, pafuramidine maleate (pafuramidine), in Europe for the treatment of pneumocystis pneumonia (PCP) in AIDS patients and for the treatment of Human African trypanosomiasis, also known as African sleeping sickness.

5 Dec 2007

Re-engineered Gleevec reduces heart risks

Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib - best known by its brand name Gleevec - to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.

4 Dec 2007

New genetic findings on malaria parasite

The malaria parasite has been studied for decades, but surprisingly, little is known about how it behaves in humans to cause disease.

29 Nov 2007

New technique provides stem cells without ethical and legal constraints

In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.

21 Nov 2007

New technique enables the detection of biomolecules' dynamic reactions in a single living cell

By taking advantage of the signature frequency by which organic and inorganic molecules absorb light, the team of researchers, led by Luke Lee, professor of bioengineering and director of UC Berkeley's Biomolecular Nanotechnology Center, can determine in real time whether specific enzymes are activated or particular genes are expressed, all with unprecedented resolution within a single living cell.

19 Nov 2007

New drug may restore memory with Alzheimer's disease

A 2006 study by MetLife found that adults over age 55 fear Alzheimer's disease more than cancer, and with good reason. Alzheimer's creeps up on patients and their families, robbing more than half of all Americans over age 85 of their memory and ability to care for themselves.

14 Nov 2007